Who Are the “Players” Involved in Biomarker Testing?
Hear Their Perspectives
Understanding the role of mutations and biomarker testing in GIST is one of most important things that GIST patients need to learn. Knowing the driving force behind each individual’s tumors is not just important, it is critical in determining the most effective treatment for your mutation. Whether it is a pathologist, an oncologist, or the laboratory doing the testing, they each play a key role in the testing process. Learn from different perspectives and ask questions to this distinguished panel of experts.
If you have questions about this presentation
or about registration, please contact:
Jonathan Trent, MD, PhD
Director, Sarcoma Oncology
Sylvester Comprehensive Cancer Center
Dr. Jonathan C. Trent is currently the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center. Dr. Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. The major efforts of Dr. Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.
Leylah Drusbosky, PhD
Medical Science Liaison
Leylah Drusbosky received her PhD in molecular biology from the University of Florida and has expertise in next generation sequencing, liquid biopsy, precision medicine, and translational research. She is a Medical Science Liaison at Guardant Health, a company that leverages liquid biopsy to guide personalized treatments in patients with advanced cancer and has a passion for communicating the need for comprehensive genomic profiling to identify the best treatment approach based on each patient’s unique disease biology.
Keith Killian, PhD
Senior Pathologist & Associate Medical Director
Dr. Killian is Senior Pathologist and Associate Medical Director at Foundation Medicine. He also serves as the lead pathologist on the partnership with Genentech to develop comprehensive gene expression profiling assays for clinical trial use. Notable prior translational medicine achievements include working with clinicians from the NIH Pediatric Gastrointestinal Stromal Tumor (GIST) clinic to discover the bimodal molecular pathologic mechanism of GIST tumorigenesis, whereby reciprocal epigenetic and genetic inactivation of succinate dehydrogenase (SDH) explain SDH deficiency in KIT/kinase-WT GIST. Other recent work includes the methyl-deviation index (MDI) as a prognostic marker in breast cancer; MDI can be more generally used to measure malignant cellularity, including lineage and purity, in routine biopsies. We also recently discovered the remarkable convergence of epigenomic programming in pluripotent stem cells and germ-cell-tumor cells. Then, we are completing a study of the clinical utility of saliva in the molecular profiling of solid and hematologic malignancy.
Thank you to our sponsors!